Covishield and Covaxin get approval after recommendation of expert panel; DCGI convenes press conference at 11 am | Indigenous Kovacsin and Kovishield's final approval, Modi said - a matter of pride for every Indian » India News
Connect with us

India News

Covishield and Covaxin get approval after recommendation of expert panel; DCGI convenes press conference at 11 am | Indigenous Kovacsin and Kovishield’s final approval, Modi said – a matter of pride for every Indian

Published

2 weeks ago

on

  • Hindi news
  • National
  • Covishield and Covaxin Get Approval After Recommendation of Expert Panel; DCGI Convenes Press Conference At 11 Am

Fed up with Ads? Install Dainik Bhaskar app for news without ads

new Delhi7 minutes ago

The wait of the people of the country for the Corona vaccine is over. Indigenous Kovaxin of Bharat Biotech and the Emergency Use of Kovshield of Serum Institute have been approved by the Drugs Controller General of India (DCGI). At the same time, Zaykov-D of Zydus Cadila Healthcare has received the approval of Phase-3 trial. DCGI VG Somani gave this information at a press conference on Sunday.

DCGI said – Vaccine 110% safe
Somani said that some side effects like mild fever, pain and allergies are common in every vaccine, but both these vaccines are 110% safe. Things like being impotent with a vaccine are nonsense.

Modi said- It is a matter of pride to get approval for 2 vaccines

WHO said – fight against Corona will be strong
The World Health Organization (WHO) has welcomed the decision to approve the vaccine. Regional Director of WHO South-East Asia, Dr. Poonam Kshetrapal Singh said that this decision of India will strengthen the fight against epidemic in South-East Asia.

CEO of Serum Institute said – ready for vaccine supply

Congress questions approval of covaxin
Congress leader Shashi Tharoor said that phase-3 trial of Kovaxin has not been done yet. It has been given hasty approval, it can be dangerous. The Health Minister should clear the situation in this regard. Kovaxin should not be used until the trial is complete.

Vaccination may start next week
The Subject Expert Committee on Corona on Saturday recommended conditional approval of Bharat Biotech to Covaxin for emergency use. Earlier on Friday, the CoviShield of the Serum Institute was recommended to give a similar approval. With the approval of both, it is now expected that the vaccination drive will also start from next week. Vaccination dry run has also started in the entire country to test the preparations.

What is typical of covaxin?

  • The results of phase-2 clinical trials of covaxin were revealed on 23 December. The trials were conducted on 380 healthy children and adults.
  • Two formulations of 3 µg and 6 µg were decided. Two groups were formed. He was given two doses with a difference of four weeks.
  • In phase-2 trials, covaxin produced high level antibodies. Even after 3 months of the second vaccination, the number of antibodies in all volunteers appeared to be increasing.
  • Based on the results of the trial, the company claims that due to covaxin, the antibodies made in the body last for 6 to 12 months.
  • Antibody is the protein present in the body which neutralizes the attack of viruses, bacteria, fungi and parasites.
  • The company claims that for Phase-3, the highest number of trials was done on 23,000 volunteers across the country.

What is special about Kovyshield?

  • Analysis of Coveshield’s clinical trials has yielded very good results. Volunteers first half dose and then full dose. No one has seen any serious health problems.
  • Ifficacy received 90% when half dose was given. A month later he was given a full dose. If both full doses were given, the efficency remained at 62%.
  • The average efficency in both types of doses was 70%. All the results are significant in terms of data. Volunteers’ blood samples and immunogenicity tests will be done until one year after the vaccine is administered to find out the efficacy. Samples are being taken every week to check for infection.
  • CoveShield is also cheaper than other vaccines.

3 crore people will be vaccinated for free
Union Health Minister Dr. Harsh Vardhan said earlier that the corona vaccine will be free in the entire country. Then an hour and a half later said that in the first phase it will be free for 30 million people. These will include 1 crore healthcare workers and 2 crore frontline workers. According to the Ministry of Health, the vaccination team will have 5 members.

Vaccine approval approved in these countries except India

  • In the US, Pfizer and Moderna’s vaccine has received emergency use approval.
  • The UK has approved the Pfizer and AstraZeneca vaccines. Vaccination is going on here.
  • China has recently approved the vaccine of indigenous company Sinopharm with certain conditions.
  • Mass vaccination has also been introduced in Russia through indigenous vaccine Sputnik V.
  • Canada has approved the vaccines of Pfizer and BioNotech.
Related Topics:
Advertisement

bareilly